Conditions: Arthritis, Rheumatoid
Keywords: Phase 1
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 148
Healthy volunteers: no

Brief summary:
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: CP-690,550 or Placebo intervention 2: Placebo
Intervention descriptions: intervention 1: CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days intervention 2: Placebo BID orally, approximately 72 days

Protocol document: